Animal experiment device combining gastroesophageal reflux chest pain modeling and treatment

Abstract

The utility model relates to an animal experiment device. The utility model discloses a gastroesophageal reflux chest pain modeling and treatment combined animal experiment device. The animal experiment device comprises a centralized sleeve, a fixed gastric sac assembly, an esophageal physical stimulation balloon assembly and a medicine stimulation assembly, the fixed gastric sac assembly comprises a first fixed balloon and a first fixed pipeline; the esophagus physical stimulation balloon assembly comprises a second stimulation balloon and a second stimulation pipeline; the medicine stimulation assembly comprises a medicine injection pipe, the medicine injection pipe and the concentration sleeve are arranged inside and outside, and the lower end of the medicine injection pipe is provided with a medicine injection opening which extends outwards and is in butt joint with the outer side of the concentration sleeve. And the lower end part of the concentration sleeve is sequentially provided with an injection part which is butted and communicated with the medicine injection port, a second fixing part for fixing the second stimulation balloon and a first fixing part for fixing the first fixing balloon from top to bottom. By means of the medicine stimulation assembly and the esophagus physical stimulation balloon assembly, switching use or combined use of chemical stimulation and physical stimulation is achieved for modeling.

Description

Technical Field

[0001] This utility model relates to the field of animal experimental technology, specifically to animal experimental devices. Background Technology

[0002] Gastroesophageal reflux disease (GERD) is a common condition characterized by the reflux of stomach contents into the esophagus, leading to a range of uncomfortable symptoms, particularly chest pain. Its development is attributed to a combination of factors, including lower esophageal sphincter dysfunction, excessive gastric acid secretion, and delayed gastric emptying. These factors result in the chronic irritation of the esophageal mucosa by gastric acid and other contents, causing inflammation and potentially leading to complications such as esophageal stricture and ulcers. Currently, animal models of GERD have become important tools for studying the mechanisms of this disease and the efficacy of treatments.

[0003] Existing animal modeling methods mainly include chemical induction, mechanical stimulation, and physiological intervention. Taking chemical induction as an example, researchers typically use strong acidic solutions (such as sodium hydroxide or hydrochloric acid) to induce esophageal mucosal damage in small animals, thus simulating the symptoms of gastroesophageal reflux. The advantage of this method is its relative simplicity and low cost, but it also suffers from poor reproducibility and significant individual variability among animals. Mechanical stimulation usually induces esophageal contraction through ethylene oxide or other methods, thereby affecting the normal transport of food. While this method can effectively induce chest pain in experiments, its significant harm to animals can sometimes affect the accuracy of research results. In addition, some researchers use electrophysiological intervention to simulate chest pain by modulating nerve signal transmission; however, this method requires advanced equipment, has a high technical threshold, and increases costs accordingly.

[0004] The current modeling methods for gastroesophageal reflux chest pain have several technical limitations. In chemical induction methods, commonly used chemical reagents are highly corrosive, potentially causing severe systemic reactions in animals, affecting their survival rate and the stability of experimental results. Furthermore, due to the short reflux cycle of gastric juice, this method may require a prolonged induction time, and the significant differences in animal responses to drugs compromise the reproducibility of experimental data.

[0005] Mechanical stimulation methods, due to their complex structure, diverse equipment requirements, and high technical difficulty, hinder the widespread adoption of such experiments and increase the uncertainty of experimental procedures. Furthermore, methods relying on electrophysiological interventions face similar challenges. Their equipment is sophisticated, operational requirements are high, and costs are substantial, making them unsuitable for large-scale animal experiments and limiting the breadth and applicability of research.

[0006] In summary, given the aforementioned shortcomings, there is an urgent need for an animal experimental device that combines the modeling and treatment of gastroesophageal reflux chest pain. This device would effectively address the problems existing in current technologies, improve the reproducibility and effectiveness of experiments, enhance in-depth research on the disease mechanism and drug efficacy, and promote more efficient and scientific clinical research and treatment of gastroesophageal reflux chest pain. Utility Model Content

[0007] In view of the problems existing in the prior art, this utility model provides an animal experimental device that combines the modeling and treatment of gastroesophageal reflux chest pain, so as to solve at least one of the above technical problems.

[0008] To achieve the above objectives, this utility model provides an animal experimental device for the combined modeling and treatment of gastroesophageal reflux chest pain, characterized in that it includes a central cannula, a gastric fixation sac assembly, an esophageal physical stimulation balloon assembly, and a drug stimulation assembly.

[0009] The fixed gastric balloon assembly includes a first fixed balloon and a first fixed tube connected in sequence. A first sealing cap is installed at the end of the first fixed tube away from the first fixed balloon. The first fixed tube is disposed inside and outside the central cannula.

[0010] The esophageal physical stimulation balloon assembly includes a second stimulation balloon and a second stimulation tubing connected in sequence. The second stimulation tubing is connected to a pressure gauge and an inflatable balloon respectively via a three-way connector. The second stimulation tubing is disposed inside and outside the central cannula.

[0011] The drug stimulation component includes an injection tube disposed inside and outside the central sleeve. The lower end of the injection tube is provided with an injection port that extends outward and connects with the outer side of the central sleeve. The top of the injection tube extends out of the central sleeve, and a third sealing cap is installed on the top of the injection tube.

[0012] The lower end of the central cannula is provided with, from top to bottom, an injection section that connects and communicates with the injection port, a second fixing section for fixing the second stimulation balloon, and a first fixing section for fixing the first fixing balloon.

[0013] This invention secures the device to the bottom of the stomach using a fixed gastric balloon assembly. The use of a drug stimulation assembly and an esophageal physical stimulation balloon assembly allows for the switching or combined use of chemical and physical stimulation for model creation. The drug stimulation assembly also enables post-modeling drug treatment experiments.

[0014] More preferably, the lower end of the central sleeve has a hemispherical outward convex structure;

[0015] The upper end of the central sleeve is detachably connected to a sealing sleeve, and the first fixed tube, the second stimulation tube, and the drug injection tube all extend upward from the sealing sleeve out of the central sleeve.

[0016] More preferably, a manual vent valve is installed near the three-way connector of the inflatable balloon.

[0017] This facilitates quantitative control of the pressure in the second stimulation balloon, thereby enabling standardized modeling. Inflatable balloons with manual venting valves are commercially available products and will not be described in detail in this application.

[0018] More preferably, the lower end of the injection tube is provided with at least two circumferentially arranged injection ports;

[0019] The injection unit has at least two circumferentially arranged injection zones, and each injection zone has at least three injection holes;

[0020] Each injection zone is connected to the injection port.

[0021] More preferably, both the first sealing cap and the third sealing cap are rubber plugs.

[0022] It facilitates injection via a needle syringe.

[0023] More preferably, both the first fixation balloon and the second stimulation balloon are arranged in a ring around the outside of the central cannula.

[0024] Compared with the prior art, the beneficial effects of this utility model are:

[0025] This invention effectively ensures the consistency and reproducibility of animal models, overcoming the problems of large individual differences and significant fluctuations in experimental data in existing technologies. The device design combines chemical and physical stimulation to better simulate the actual situation of gastroesophageal reflux. Preliminary experimental comparisons show that this device achieves over 90% reproducibility in inducing gastroesophageal reflux-induced chest pain, while traditional methods generally have reproducibility below 70%. This reliability ensures the credibility of subsequent research data and provides the scientific community with a standardized experimental tool.

[0026] In this invention, a gastric fixation device is provided. After the first fixation balloon of the gastric fixation assembly is inflated with air or water, it is fixed to the bottom of the stomach for modeling and drug injection. After the device is fixed, the second stimulation balloon is inflated by manually pressing the inflatable balloon. The appropriate pressure is used to expand the esophageal wall of the lower esophagus to form erosions. The acidic modeling drug can be injected through the injection tube and sprayed out through the injection part to directly act on the erosions in the lower esophagus. After successful modeling, the therapeutic drug can also be injected through the injection tube to increase the contact area between the therapeutic drug and the lesion.

[0027] 1. The second stimulation balloon of this utility model is connected to a pressure gauge, which can set the corresponding pressure during modeling to standardize the degree of lesion erosion during modeling;

[0028] 2. The present invention, through the injection section, facilitates the uniform spraying of the drug solution onto the esophageal wall during modeling or treatment, thereby improving the success rate of modeling and the efficiency of treatment.

[0029] 3. This utility model is a dual-purpose device for modeling and treatment. During modeling, the second stimulation balloon can be inflated with a certain pressure to expand the esophageal wall and form erosion in the lower esophagus. Combined with the drug injection tube, the drug is administered to form an acidic erosion lesion. During treatment, there is no need to inflate the second stimulation balloon. Only the fixed gastric balloon component is inflated / injected with water to fix the whole device. Then, the therapeutic drug can be administered from the drug injection tube and sprayed onto the esophageal lesion for treatment. Attached Figure Description

[0030] Figure 1 This is a cross-sectional view of the present invention;

[0031] Figure 2 This is a schematic diagram of one structure of the present utility model.

[0032] In the diagram: 1 is the central cannula, 2 is the occlusion sleeve, 3 is the first fixed balloon, 4 is the first fixed tubing, 5 is the second stimulating balloon, 6 is the second stimulating tubing, 7 is the pressure gauge, 8 is the inflatable balloon, 9 is the injection tubing, 10 is the tee connector, 11 is the first occlusion cap, 12 is the injection area, and 13 is the third occlusion cap. Detailed Implementation

[0033] The present invention will be further described below with reference to the accompanying drawings.

[0034] See Figure 1And Figure 2, Specific Embodiment 1: An animal experimental device for combined modeling and treatment of gastroesophageal reflux chest pain, including a central cannula 1, a fixed gastric pouch assembly, an esophageal physical stimulation balloon assembly, and a drug stimulation assembly; the fixed gastric pouch assembly includes a first fixed balloon 3 and a first fixed tubing 4 connected in sequence, the end of the first fixed tubing 4 away from the first fixed balloon 3 is equipped with a first sealing cap 11, and the first fixed tubing 4 is disposed inside and outside the central cannula 1; the esophageal physical stimulation balloon assembly includes a second stimulation balloon 5 and a second stimulation tubing 6 connected in sequence, the second stimulation tubing 6 being connected to the central cannula 1 The device is internally and externally configured. The second stimulation line 6 is connected to the pressure gauge 7 and the inflatable balloon 8 via a three-way connector 10. The drug stimulation component includes an injection tube 9, which is internally and externally configured with a central sleeve 1. The lower end of the injection tube 9 has an injection port that extends outward and connects with the outer side of the central sleeve 1. The top of the injection tube 9 extends out of the central sleeve 1, and a third sealing cap 13 is installed on the top of the injection tube 9. The lower end of the central sleeve 1 has, from top to bottom, an injection section that connects with the injection port, a second fixing section for fixing the second stimulation balloon 5, and a first fixing section for fixing the first fixing balloon 3. This invention achieves device fixation at the bottom of the stomach through the gastric balloon fixing component. The drug stimulation component and the esophageal physical stimulation balloon component enable the switching or combined use of chemical stimulation and physical stimulation for modeling. The drug stimulation component can also be used for post-modeling drug treatment experiments.

[0035] After the first fixation balloon is inflated, it is fixed inside the stomach near the gastric tube, that is, in the fundus region.

[0036] The maximum outer diameter of the first fixed balloon after inflation is greater than the maximum outer diameter of the second stimulation balloon after inflation.

[0037] The second stimulation balloon has a longer axial length than the first fixed balloon. Spherical protrusions are provided on the outer wall of the second stimulation balloon to facilitate the accelerated formation of erosive lesions.

[0038] The axial distance between the second stimulation balloon and the first fixed balloon is greater than 1 cm. The axial length of the second stimulation balloon is 3 cm.

[0039] The lower end of the central sleeve 1 is a hemispherical outward convex structure; the upper end of the central sleeve 1 is detachably connected to a sealing sleeve 2, and the first fixed tube 4, the second stimulation tube 6 and the drug injection tube 9 all extend upward from the sealing sleeve 2 out of the central sleeve 1.

[0040] A manual vent valve is installed near the T-connector of the inflatable balloon 8. This facilitates quantitative control of the pressure of the second stimulation balloon, thereby achieving standardized molding. Inflatable balloons with manual vent valves are commercially available products, therefore they will not be described in detail in this application.

[0041] The lower end of the injection tube 9 is provided with at least two circumferentially arranged injection ports; the injection section is provided with at least two circumferentially arranged injection zones 12, each injection zone 12 is provided with at least three injection holes; the injection holes of each injection zone are connected to the injection ports one by one.

[0042] Both the first and third sealing caps are rubber stoppers, facilitating injection via a needle syringe.

[0043] Both the first fixed balloon 3 and the second stimulating balloon 5 are arranged in a ring around the outside of the central cannula 1.

[0044] Pressure gauge 7 is connected to the pressure gauge cover via a rotating shaft.

[0045] The animal experiment procedure for this device is as follows: after inflating or injecting water into the first fixation balloon 3 of the fixation gastric balloon assembly, the first fixation balloon is fixed in the gastric fundus region to facilitate modeling and drug injection.

[0046] After the device is fixed, the second stimulation balloon 5 is inflated by manually pressing the inflatable balloon 8. The appropriate pressure is used to expand the esophageal wall of the lower esophagus and form erosion foci. The acidic modeling drug can be injected through the injection tube 9 and sprayed out through the injection part to directly act on the erosion foci of the lower esophagus.

[0047] After successful modeling, the therapeutic drug can also be injected through the injection tube 9 to increase the contact area between the therapeutic drug and the lesion.

[0048] The above are merely preferred embodiments of this utility model. It should be noted that, for those skilled in the art, several improvements and modifications can be made without departing from the principle of this utility model, and these improvements and modifications should also be considered within the protection scope of this utility model.

Claims

1. An animal experimental device for combining the creation and treatment of gastroesophageal reflux chest pain model, characterized in that, It includes a central cannula, a fixed gastric balloon assembly, an esophageal physical stimulation balloon assembly, and a drug stimulation assembly; The fixed gastric balloon assembly includes a first fixed balloon and a first fixed tube connected in sequence. A first sealing cap is installed at the end of the first fixed tube away from the first fixed balloon. The first fixed tube is disposed inside and outside the central cannula. The esophageal physical stimulation balloon assembly includes a second stimulation balloon and a second stimulation tubing connected in sequence. The second stimulation tubing is connected to a pressure gauge and an inflatable balloon respectively via a three-way connector. The second stimulation tubing is disposed inside and outside the central cannula. The drug stimulation component includes an injection tube disposed inside and outside the central sleeve. The lower end of the injection tube is provided with an injection port that extends outward and connects with the outer side of the central sleeve. The top of the injection tube extends out of the central sleeve, and a third sealing cap is installed on the top of the injection tube. The lower end of the central cannula is provided with, from top to bottom, an injection section that connects and communicates with the injection port, a second fixing section for fixing the second stimulation balloon, and a first fixing section for fixing the first fixing balloon.

2. The animal experimental device for combining the establishment and treatment of gastroesophageal reflux chest pain modeling according to claim 1, characterized in that: The lower end of the central sleeve has a hemispherical outward convex structure; The upper end of the central sleeve is detachably connected to a sealing sleeve, and the first fixed tube, the second stimulation tube, and the drug injection tube all extend upward from the sealing sleeve out of the central sleeve.

3. The animal experimental device for combining the modeling and treatment of gastroesophageal reflux chest pain according to claim 1, characterized in that: A manual vent valve is installed near the tee connector on the inflatable balloon.

4. The animal experimental device for combining the modeling and treatment of gastroesophageal reflux chest pain according to claim 1, characterized in that: The lower end of the injection tube is provided with at least two circumferentially arranged injection ports; The injection unit has at least two circumferentially arranged injection zones, and each injection zone has at least three injection holes; Each injection zone is connected to the injection port.

5. The animal experimental device for combining the modeling and treatment of gastroesophageal reflux chest pain according to claim 1, characterized in that: Both the first sealing cap and the third sealing cap are rubber plugs.

6. The animal experimental apparatus for combining the modeling and treatment of gastroesophageal reflux chest pain according to claim 1, characterized in that: Both the first fixation balloon and the second stimulation balloon are arranged in a ring around the outside of the central cannula.

Images